Tyrosine kinase inhibitors for CML, such as imatinib, only target cells that carry the BCR:ABL mutation while leaving healthy cells unscathed (Rowley, 1973). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.